Compare LINC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | ANNX |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 730.4M |
| IPO Year | 2005 | 2020 |
| Metric | LINC | ANNX |
|---|---|---|
| Price | $36.27 | $5.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $37.50 | $16.50 |
| AVG Volume (30 Days) | 472.4K | ★ 1.7M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $261,853,000.00 | N/A |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | $150.39 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $14.10 | $1.29 |
| 52 Week High | $36.42 | $7.18 |
| Indicator | LINC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 77.68 | 52.94 |
| Support Level | $21.46 | $4.65 |
| Resistance Level | N/A | $7.18 |
| Average True Range (ATR) | 1.86 | 0.32 |
| MACD | 0.72 | 0.00 |
| Stochastic Oscillator | 98.17 | 78.71 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.